Prof. Arnon Nagler from Tel Aviv University, Tel Aviv, IL, discusses at 44th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting the use of immune checkpoint inhibitors for the prevention of post-transplantation relapse in patients with acute myeloid leukemia. Leukemia cells express PD-L1, which they use to evade the immune system and cause relapse. Using checkpoint inhibitors such as nivolumab, a PD-1 inhibitor, might be a strategy to prevent post-transplant relapse in AML patients.
The European LeukemiaNet (ELN) is a non-profit charitable organisation funded by donations and based on an established network of excellence where clinicians and scientists improve therapy options for leukemia patients worldwide. The ELN addresses every individual and all groups dedicated to fight leukemia - from medical doctors, researchers, healthcare professionals, patients and their relatives to private and public organisations and charities.